<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242371</url>
  </required_header>
  <id_info>
    <org_study_id>SMRI/SPHS 2010-01</org_study_id>
    <nct_id>NCT01242371</nct_id>
  </id_info>
  <brief_title>Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheppard Pratt Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheppard Pratt Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to explore the hypothesis that symptoms of schizophrenia may be
      reduced by the administration of a probiotic supplement when used in addition to standard
      antipsychotic medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the current study is:

        1. To evaluate the safety and efficacy of a supplemental probiotic therapy, containing the
           microorganisms Lactobacillus rhamnosus GG and Bifidobacterium lanimalis subsp. lactis
           (BB12), for individuals with schizophrenia who have residual psychotic symptoms of at
           least moderate severity.

           Secondary aims of the study are:

        2. To assess the effect of probiotic treatment on patients' gastrointestinal functioning

        3. To study the effect of probiotic treatment in lowering the levels of antibodies to
           casein and gliadin.

        4. To investigate the association between the efficacy of probiotic therapy and initial
           levels of antibodies to gliadin and casein.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase (Week 0 to Week 14)</measure>
    <time_frame>14 weeks (week 0 to week 14)</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Functioning From the Beginning to the End of the Double-blind Treatment Phase Weeks 0-14</measure>
    <time_frame>14 weeks (weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 &amp; 14)</time_frame>
    <description>Self report rating of difficulty moving bowels on a 4 point scale from &quot;no difficulty&quot; to &quot;severe difficulty&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Gliadin and Casein Antibody Levels</measure>
    <time_frame>16 weeks (baseline prior to placebo run in to week 14)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Probiotic Supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Identical-appearing Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic Supplement</intervention_name>
    <description>Probiotic Supplement 1 tablet by mouth daily</description>
    <arm_group_label>Probiotic Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Identical-appearing Placebo</intervention_name>
    <description>Probiotic identical placebo 1 tablet by mouth daily</description>
    <arm_group_label>Identical-appearing Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65.

          -  Capacity for written informed consent.

          -  Primary Axis I diagnosis (DSM-IV) of schizophrenia, any type, OR schizoaffective
             disorder (APA, 1994).

          -  Currently an outpatient at the time of enrollment.

          -  Residual psychotic symptoms which are at least moderately severe as evidenced by one
             or more PANSS positive symptom scores, and/or PANSS negative symptom scores of 4 or
             more; OR a total PANSS score of 50 or more, containing at least three positive or
             negative items with scores of 3 or more at screening.

          -  Conformance to PORT Treatment Recommendation re Maintenance Antipsychotic Medication
             Dose (Buchanan et al., 2010).

          -  Receiving antipsychotic medication for at least 8 weeks prior to starting the study
             with no medication changes within the previous 21 days.

          -  Proficient in the English language.

        Exclusion Criteria:

          -  Diagnosis of mental retardation.

          -  Any clinically significant or unstable medical disorder as determined by the
             investigators, including congestive heart failure, abnormal liver function or disease,
             renal failure, acute pancreatitis, any diagnosis of cancer undergoing active
             treatment, HIV infection or other immunodeficiency condition.

          -  History of IV drug use.

          -  Primary diagnosis of substance abuse or dependence according to DSM-IV criteria within
             the last three months.

          -  Participated in any investigational drug trial in the past 30 days.

          -  Pregnant or planning to become pregnant during the study period.

          -  Receipt of antibiotic medication within the previous 14 days (as anaerobic organisms
             residing in the gastrointestinal tract may be minimally affected by antibiotics).

          -  Documented celiac disease (as such persons should be on a gluten-free diet as this is
             the standard care).

          -  Of note, the investigators are not limiting the study to individuals with elevated
             levels of gliadin or casein antibodies as the investigators intend to look at these
             levels as a predictor of response.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faith B Dickerson, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheppard Pratt Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheppart Pratt Health System</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>November 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2010</study_first_posted>
  <results_first_submitted>August 29, 2013</results_first_submitted>
  <results_first_submitted_qc>August 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2013</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheppard Pratt Health System</investigator_affiliation>
    <investigator_full_name>Faith Dickerson, PhD, MPH</investigator_full_name>
    <investigator_title>Head, Stanley Research Program</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective</keyword>
  <keyword>Probiotic supplements</keyword>
  <keyword>Gliadin</keyword>
  <keyword>Casein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled n=65 participants drawn from rehabilitation and treatment programs in Central Maryland. Dates of recruitment 11/2010-01/2012.</recruitment_details>
      <pre_assignment_details>We used a 2 week placebo run in for all participants prior to randomization. This placebo run in was followed by the 14 week double-blind treatment phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Probiotic Supplement</title>
          <description>Probiotic supplement 1 tablet by mouth daily for 14 weeks</description>
        </group>
        <group group_id="P2">
          <title>Identical-appearing Placebo</title>
          <description>Identical appearing placebo 1 tablet by mouth daily for 14 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Probiotic Supplement</title>
          <description>Probiotic supplement 1 tablet by mouth daily for 14 weeks</description>
        </group>
        <group group_id="B2">
          <title>Identical-appearing Placebo</title>
          <description>Identical appearing placebo 1 tablet by mouth daily for 14 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="11.0"/>
                    <measurement group_id="B2" value="48.1" spread="9.4"/>
                    <measurement group_id="B3" value="46.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase (Week 0 to Week 14)</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.</description>
        <time_frame>14 weeks (week 0 to week 14)</time_frame>
        <population>Week 0 data is based on the number of participants in the probiotic supplement group (n=33) and the placebo group (n=32) who began the treatment phase. Week 14 data is based on the number of participants in the probiotics supplement group (n=31) and the placebo group (n=27) who completed the treatment phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Probiotic Supplement</title>
            <description>Probiotic supplement 1 tablet by mouth daily for 14 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical appearing placebo 1 tablet by mouth daily for 14 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase (Week 0 to Week 14)</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.</description>
          <population>Week 0 data is based on the number of participants in the probiotic supplement group (n=33) and the placebo group (n=32) who began the treatment phase. Week 14 data is based on the number of participants in the probiotics supplement group (n=31) and the placebo group (n=27) who completed the treatment phase.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 0 (Begin Treatment) PANSS Total Score, n=33,32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.55" spread="11.64"/>
                    <measurement group_id="O2" value="69.56" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 14 (End Treatment) PANSS Total Score, n=31,27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.42" spread="11.66"/>
                    <measurement group_id="O2" value="67.69" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal Functioning From the Beginning to the End of the Double-blind Treatment Phase Weeks 0-14</title>
        <description>Self report rating of difficulty moving bowels on a 4 point scale from &quot;no difficulty&quot; to &quot;severe difficulty&quot;</description>
        <time_frame>14 weeks (weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 &amp; 14)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Gliadin and Casein Antibody Levels</title>
        <time_frame>16 weeks (baseline prior to placebo run in to week 14)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a 16 week period, including the 2 week placebo run in and the 14 week double-blind treatment phase.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Probiotic Supplement</title>
          <description>Probiotic supplement 1 tablet by mouth daily for 14 weeks</description>
        </group>
        <group group_id="E2">
          <title>Identical-appearing Placebo</title>
          <description>Identical appearing placebo 1 tablet by mouth daily for 14 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia exacerbation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea was assessed separately and is counted as a separate adverse event from other gastrointestinal problems, which were solicited non-specifically.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastrointestonal symptoms (excluding diarrhea)</sub_title>
                <description>Non-specific new onset gastrointestinal symptoms including constipation, heartburn, nausea, stomach cramps, and/or flatulence. Diarrhea was assessed separately and is counted as a separate adverse event.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskelatol condition</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric condition</sub_title>
                <description>Psychiatric disease under study</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary condition</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory illness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Did not perform more detailed measures of gastrointestinal functioning or obtain a more complete history of participantsâ€™ gastrointestinal symptoms and associated treatment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Faith Dickerson</name_or_title>
      <organization>Sheppard Pratt</organization>
      <phone>410-938-4359</phone>
      <email>fdickerson@sheppardpratt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

